We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Pacific Biosciences of California (PACB - Free Report) . Shares have added about 8.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Pacific Biosciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Pacific Biosciences Q1 Earnings Surpass Estimates
Pacific Biosciences of California, Inc.reported first-quarter 2020 earnings per share of a penny against the Zacks Consensus Estimate of a loss of 15 cents. The company had reported a loss of 20 cents in the year-ago quarter.
Revenues totaled $15.6 million, which missed the Zacks Consensus Estimate by 22.4% and fell 4.9% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $12.3 million, down 8.9% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.3 million, up 13.8% year over year.
Margins
Gross profit in the first quarter was $7.5 million, up 46.3% year over year.Gross margin was 48% of total revenues, expanding 1685 basis points.
Operating expenses totaled $40.2 million, up 14% year over year.
Operating loss came in at $32.7 million, wider than the year-ago quarter’s loss of $30.1 million.
Merger Termination With Illumina
On Jan 2, 2020, Pacific Biosciences and Illumina agreed to terminate their merger agreement, which was announced in 2019.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted -23.33% due to these changes.
VGM Scores
At this time, Pacific Biosciences has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Pacific Biosciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Pacific Biosciences of California (PACB - Free Report) . Shares have added about 8.1% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Pacific Biosciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Pacific Biosciences Q1 Earnings Surpass Estimates
Pacific Biosciences of California, Inc. reported first-quarter 2020 earnings per share of a penny against the Zacks Consensus Estimate of a loss of 15 cents. The company had reported a loss of 20 cents in the year-ago quarter.
Revenues totaled $15.6 million, which missed the Zacks Consensus Estimate by 22.4% and fell 4.9% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenues: At this segment, revenues amounted to $12.3 million, down 8.9% from the prior-year quarter’s tally.
Service and Other Revenues: At this segment, revenues came in at $3.3 million, up 13.8% year over year.
Margins
Gross profit in the first quarter was $7.5 million, up 46.3% year over year.Gross margin was 48% of total revenues, expanding 1685 basis points.
Operating expenses totaled $40.2 million, up 14% year over year.
Operating loss came in at $32.7 million, wider than the year-ago quarter’s loss of $30.1 million.
Merger Termination With Illumina
On Jan 2, 2020, Pacific Biosciences and Illumina agreed to terminate their merger agreement, which was announced in 2019.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted -23.33% due to these changes.
VGM Scores
At this time, Pacific Biosciences has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Pacific Biosciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.